ArticleScientific reports2017
The synthetic neuroactive steroid SGE-516 reduces seizure burden and improves survival in a Dravet syndrome mouse model.
Article in Scientific reports, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 34 citations in OpenAlex.
- Pregnanolone-Based Prodrugs as a Strategy for Neuroprotective Drug-Like Compounds: Pregnanolone Pyroglutamate and Its Age‑dependent Anticonvulsant Effects in the 6-hz Seizure Model in Immature Rats.Drug design, development and therapy · 2026Article
- Development of a preclinical testing platform for clinically relevant therapy for Dravet syndrome.Epilepsia · 2025Article
- Emerging Insights into the Pathogenic Mechanisms of Dravet Syndrome.Neurochemical research · 2025Review
- Neuroactive steroids activate membrane progesterone receptors to induce sex specific effects on protein kinase activity.iScience · 2025Article
- Dravet syndrome: novel insights intoFrontiers in neuroscience · 2025Review
- Article
- Cell-Selective Adeno-Associated Virus-MediatedHuman gene therapy · 2022Article
- GABAkines - Advances in the discovery, development, and commercialization of positive allosteric modulators of GABAPharmacology & therapeutics · 2022Review
- Inhibition of human macrophage activationFrontiers in immunology · 2022Article
- GABA tonic currents and glial cells are altered during epileptogenesis in a mouse model of Dravet syndrome.Frontiers in cellular neuroscience · 2022Article
- Soticlestat, a novel cholesterol 24-hydroxylase inhibitor, reduces seizures and premature death in Dravet syndrome mice.Epilepsia · 2021Article
- Gabra2 is a genetic modifier of Dravet syndrome in mice.Mammalian genome : official journal of the International Mammalian Genome Society · 2021Article
- Sodium channelopathies of skeletal muscle and brain.Physiological reviews · 2021Review
- An Emerging Role for Sigma-1 Receptors in the Treatment of Developmental and Epileptic Encephalopathies.International journal of molecular sciences · 2021Review
- Development of an antiseizure drug screening platform for Dravet syndrome at the NINDS contract site for the Epilepsy Therapy Screening Program.Epilepsia · 2021Article
- Preclinical characterization of zuranolone (SAGE-217), a selective neuroactive steroid GABANeuropharmacology · 2020Article
- A 5-HTThe European journal of neuroscience · 2020Article
- C57BL/6J and C57BL/6N substrains differentially influence phenotype severity in theEpilepsia open · 2019Article
- A Novel, Synthetic, Neuroactive Steroid Is Effective at Decreasing Depression-Like Behaviors and Improving Maternal Care in Preclinical Models of Postpartum Depression.Frontiers in endocrinology · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Dravet syndrome is an infant-onset epileptic encephalopathy with multiple seizure types that are often refractory to conventional therapies. Treatment with standard benzodiazepines like clobazam, in combination with valproate and stiripentol, provides only modest seizure control. While benzodiazepines are a first-line therapy for Dravet syndrome, they are limited by their ability to only modulate synaptic receptors. Unlike benzodiazepines, neuroactive steroids potentiate a wider-range of GABA
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.